A
Ashish Bajel
Researcher at Peter MacCallum Cancer Centre
Publications - 85
Citations - 1799
Ashish Bajel is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 18, co-authored 64 publications receiving 1206 citations. Previous affiliations of Ashish Bajel include Royal Melbourne Hospital.
Papers
More filters
Journal ArticleDOI
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial
Orla Morrissey,Orla Morrissey,Sharon C.-A. Chen,Sharon C.-A. Chen,Sharon C.-A. Chen,Tania C. Sorrell,Tania C. Sorrell,Tania C. Sorrell,Sam Milliken,Peter G Bardy,Kenneth F. Bradstock,Jeff Szer,Catriona Halliday,Nicole Gilroy,John Moore,Anthony P. Schwarer,Stephen Guy,Ashish Bajel,Adrian R Tramontana,Tim Spelman,Tim Spelman,Monica A. Slavin +21 more
TL;DR: Use of aspergillus galactomannan and PCR to direct treatment reduced use of empirical antifungal treatment in high-risk haematology patients.
Journal ArticleDOI
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly,Marcelo C. Pasquini,Michael Martens,Ruta Brazauskas,Xiaochun Zhu,Kehinde Adekola,Mahmoud Aljurf,Karen K. Ballen,Ashish Bajel,Frédéric Baron,Minoo Battiwalla,Amer Beitinjaneh,Jean-Yves Cahn,Mathew Carabasi,Yi-Bin Chen,Saurabh Chhabra,Stefan O. Ciurea,Edward A. Copelan,Anita D'Souza,John R. Edwards,James M. Foran,Cesar O. Freytes,Henry C. Fung,Robert Peter Gale,Sergio Giralt,Shahrukh K. Hashmi,Gerhard C. Hildebrandt,Vincent T. Ho,Ann A. Jakubowski,Hillard M. Lazarus,Marlise R. Luskin,Rodrigo Martino,Richard T. Maziarz,Philip L. McCarthy,Taiga Nishihori,Rebecca L. Olin,Richard F. Olsson,Richard F. Olsson,Attaphol Pawarode,Edward Peres,Andrew R. Rezvani,David A. Rizzieri,Bipin N. Savani,Harry C. Schouten,Mitchell Sabloff,Matthew D. Seftel,Sachiko Seo,Mohamed L. Sorror,Mohamed L. Sorror,Jeff Szer,Baldeep Wirk,William A. Wood,Andrew S. Artz +52 more
TL;DR: Over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥70 years with hematologic malignancies across the United States.
Journal ArticleDOI
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Vinod Pullarkat,Norman J. Lacayo,Elias Jabbour,Jeffrey E. Rubnitz,Jeffrey E. Rubnitz,Ashish Bajel,Theodore W. Laetsch,Theodore W. Laetsch,Jessica Leonard,Susan Colace,Seong Lin Khaw,Shaun Fleming,Ryan J. Mattison,Robin E. Norris,Joseph T. Opferman,Kathryn G. Roberts,Yaqi Zhao,Chunxu Qu,Mohamed Badawi,Michelle Schmidt,Bo Tong,John Pesko,Yan Sun,Jeremy A. Ross,Deeksha Vishwamitra,Lindsey Rosenwinkel,Su Young Kim,Amanda Jacobson,Charles G. Mullighan,Thomas B. Alexander,Wendy Stock +30 more
TL;DR: Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy.
Journal ArticleDOI
Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014
Shaun Fleming,Costas K Yannakou,Gabrielle M Haeusler,Gabrielle M Haeusler,Julia E Clark,Andrew Grigg,Christopher H. Heath,Christopher H. Heath,Ashish Bajel,S. J. van Hal,Sharon C.-A. Chen,Sharon C.-A. Chen,Sam Milliken,Sam Milliken,C. O. Morrissey,Constantine S. Tam,Constantine S. Tam,Jeff Szer,Jeff Szer,Robert Weinkove,Robert Weinkove,Monica A. Slavin,Monica A. Slavin +22 more
TL;DR: These guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic with significant mortality associated with invasive fungal disease and a focus on refining and simplifying patient risk stratification.
Journal ArticleDOI
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Michelle Ananda-Rajah,Andrew Grigg,Maria T. Downey,Ashish Bajel,Tim Spelman,Allen C. Cheng,Karin A Thursky,Janette M. Vincent,Monica A. Slavin +8 more
TL;DR: Adoption of voriconazole/posaconazole has decreased invasive fungal disease incidence, empiric antifungal treatment and for posaconzole, computed-tomography demand, with effectiveness of posaconazoles comparable to clinical trial experience.